July 18 (Reuters) - GENEURO SA GNRO.PA :
* CASH POSITION OF EUR 10.1 MILLION AT JUNE 30, 2019
* SUCCESSFUL FINAL 12-MONTH RESULTS FROM PHASE 2A TYPE 1
DIABETES
TRIAL
* CONSTRUCTIVE PARTNERING DISCUSSIONS FOR LEAD PRODUCT
TEMELIMAB
CONTINUING, FOLLOWING POSITIVE RESULTS FROM ANGEL-MS
* COMPANY RECOGNIZED NO REVENUES IN Q2 OF 2019
* AVAILABLE CASH RESOURCES PROVIDE GENEURO WITH SOLID
FINANCIAL
VISIBILITY UNTIL MID-2020 COVERING ALL PLANNED ACTIVITIES
* COMPANY RECOGNIZED NO REVENUES IN Q2 OF 2019.
Source text for Eikon: ID:nBw4PNr0Na
Further company coverage: GNRO.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com;))